INTRODUCTION
The ability to alter metabolic output to fulfill the biosynthetic and bioenergetic demands of cell growth and proliferation is a defining feature of cancer cells (Cairns et al., 2011; Vander Heiden et al., 2011; Ward and Thompson, 2012) . For example, the Myc oncogene reprograms several cellular machineries, including those promoting protein synthesis, glycolysis, glutaminolysis, and nucleotide synthesis, all of which are vital for sustaining cancer cell survival (Dang, 2010; Gordan et al., 2007; Liu et al., 2008; Mannava et al., 2008; Morrish et al., 2008; Wise et al., 2008 ). An outstanding question is how cancer cells couple multiple macromolecular synthetic processes to sustain an enhanced bioenergetic homeostasis vital for cancer cell survival. For instance, cancer cells need to maintain a careful homeostasis between the rate of protein biosynthesis and the metabolic flux that supplies the biosynthetic precursors and energy necessary for cancer cell growth and survival. In particular, the increased rate of protein synthesis that sustains cancer cell growth upon Myc hyperactivation imposes an onerous biosynthetic and bioenergetic cost to cancer cells (Bywater et al., 2013; Granneman and Baserga, 2004; Lempiä inen and Shore, 2009; White, 2008) . Therefore, an unanswered question is how key cellular processes underlying cancer cell growth, such as metabolism and protein synthesis, become coordinated and are maintained, and whether this point of intersection reflects a unique vulnerability that could be targeted. This question is particularly critical, as the Myc oncogene, at present, remains ''undruggable.'' In this work, we employed a multifaceted approach integrating metabolomics with a unique mouse genetic strategy to address how production of two of the most abundant classes of cellular macromolecules, proteins and nucleic acids, are integrated and coupled by the Myc oncogene. Surprisingly, we find that Mycdriven hyperactivation of protein synthesis stimulates the translational upregulation of one key rate-limiting enzyme, PRPS2, within the nucleotide biosynthesis pathway. Many translationally regulated transcripts downstream of mTOR hyperactivation harbor a pyrimidine-rich translational element (PRTE) positioned within their 5 0 UTR (Hsieh et al., 2012) . Interestingly, we find that Prps2 contains a PRTE that enables translational regulation by Myc to directly increase nucleotide biosynthesis proportionately to the increased protein synthesis rates of cancer cells. Strikingly, PRPS1, a related isoform that is responsible for widespread effects on nucleotide metabolism in normal cells, lacks the PRTE cis-regulatory translational element within its 5 0 UTR, thereby revealing a distinguishing feature of an isoform-specific PRPS in cancer cells. Therefore, these findings delineate a self-regulating circuitry through which cancer cells ensure balanced coordination between the production of proteins and nucleic acids. Importantly, by specifically inhibiting expression of Prps2, we demonstrate synthetic lethality in Myc-overexpressing cells and dramatically decreased tumorigenic potential in vivo, illuminating an important vulnerability and therapeutic window for cancers driven by ''undruggable'' oncogenes, such as Myc.
RESULTS

Elevated Rates of Protein Synthesis Sustain the MycDependent Metabolic Program
It remains unknown whether and how the elevated metabolic and protein synthesis programs of cancer cells are sensed and coupled to promote cancer cell growth and development. We first sought to genetically determine whether Myc's ability to increase the protein synthetic capacity of cancer cells is directly linked to enhanced metabolism. The Em-Myc/+ transgenic mouse faithfully recapitulates the clinical features of human Burkitt's lymphoma (Adams et al., 1985; Harris et al., 1988) . B cells derived from these mice display a dramatic increase in Mycdependent ribosome biogenesis and protein synthesis, resulting in increased cell growth, which is a hallmark of Myc-driven cancers (Barna et al., 2008; Iritani and Eisenman, 1999) . Previous studies have revealed that haploinsufficiency of a single ribosomal protein (RP), RPL24, leads to an overall decrease in protein synthesis and that RPL24 haploinsufficiency in the Em-Myc/+ genetic background is sufficient to restrain Mycdependent hyperactivation of protein synthesis to normal levels, dramatically thwarting Myc's oncogenic activity (Barna et al., 2008 Figure 1A ). Consistent with an overall shift in metabolic processes to an anabolic state, we find that Myc-overexpressing cells, both in the pretumor and in the tumor setting, display an overall depletion in formate, acetate, and propionate, which are used for the construction of larger, more complex metabolites, such as nucleotides, lipids, and amino acids ( Figure 1B ). We also find that in the pretumor setting, Myc broadly increases the levels of metabolites frequently found increased in cancer cells, such as purine nucleotides, choline, phosphocholine, acetylcarnitine, and several amino acids, such as glycine and proline ( Figure 1B) . However, there also appears to be cell-type specificity. For example, the levels of glutamine or lactate previously linked to Myc-dependent metabolism are not altered in Em-Myc/+ B cells (Wise et al., 2008; Yuneva et al., 2012) . The changes observed in the pretumor setting are maintained and, in most cases, amplified in the Myc-driven malignant lymphoma setting. We directly ascertained how elevated protein synthesis rates in cancer influence the cancer metabolome. Strikingly, in EmMyc/+;Rpl24 BST/+ B cells, we observed a specific rescue in a subset of metabolites normally found elevated in Em-Myc/+ cells. Unexpectedly, the most notable class of such metabolites is the nucleotides IMP, AMP, ADP, and ATP (Figures 1B and 1C, inset) . The observed rescue in nucleotide metabolite production in Em-Myc/+ compared to Em-Myc/+;Rpl24 BST/+ B cells was also further validated by high-performance liquid chromatography (HPLC) ( Figure S1A available online) and a PCR-based assay to measure free dNTP concentrations from a complex mixture of intracellular metabolites ( Figure S1B ). Together, these findings suggest that augmented protein biosynthesis may be directly coupled to the control of nucleotide metabolism downstream of Myc hyperactivation, revealing an unexpected coordination between the production of the two most abundant classes of macromolecules in cancer cells: proteins and nucleic acids.
PRPS2 Is a Critical Rate-Limiting Enzyme-Integrating Myc-Dependent Protein Synthesis with Nucleotide Metabolism Elevated nucleotide pools, through either de novo synthesis from carbohydrate and amino acid precursors or by salvage enzymes that rejoin recycled nucleobase and sugar moieties, are a defining feature of many cancer cells, required to carry out a diverse array of cellular functions (Tong et al., 2009) . The effect of Myc on nucleotide levels is due, in large part, to increases in rates of de novo purine biosynthesis as revealed by the increased incorporation of radiolabeled precursors ([ 14 C]-formate) for the de novo synthesis pathway ( Figure 1D ). Our findings also show that Myc increases nucleotide production by promoting flux through the purine salvage pathway (Figure 1E) . Overall, these experiments suggest that Myc-dependent control of purine nucleotide concentrations relies on the increased biosynthetic production of purine precursors. We next asked whether Myc-dependent increases in protein synthesis influence the expression of one or several key enzymes upstream or within the purine biosynthetic pathway. We identified a critical rate-limiting enzyme of purine biosynthesis, phosphoribosyl-pyrophosphate synthetase 2 (PRPS2), as a translationally regulated mRNA whose protein levels are increased upon Myc overexpression and restored to wild-type (WT) levels in Em-Myc/+;Rpl24 BST/+ -derived B cells (Figures 1F and 1G) . This effect on posttranscriptional control of Prps2 is highly specific as, notably, other important enzymes involved in nucleotide metabolism are expressed similarly in Em-Myc/+ and Em-Myc/+;Rpl24 BST/+ B cells ( Figures 1F, 1G , and S1C).
Therefore, these results unexpectedly suggest that one key enzyme within the purine biosynthesis pathway may be directly coupled to increased rates of protein synthesis elicited by the Myc oncogene to further regulate the flow of metabolic intermediates through the entire nucleotide pathway. Phosphoribosyl pyrophosphate synthetase (PRPS) activity plays a central metabolic role in the production of nucleotides. The PRPS enzyme adds a pyrophosphate group donated from ATP to ribose-5-phosphate generated from the pentose phosphate pathway to produce 5-phosphoribosyl-1-pyrophosphate (PRPP) (Figure 2A ). PRPP is a substrate for all nucleotide salvage pathway enzymes, as well as the rate-limiting enzymes of purine and pyridine biosynthesis. Because the K M rate constants of nucleotide biosynthetic pathway enzymes that utilize PRPP as a substrate far exceed the physiological intracellular concentrations of this metabolite, an increase in PRPP levels may be sufficient to govern the overall nucleotide biosynthetic rate of cells. Therefore, we next addressed whether PRPS2 as a single enzyme is necessary and sufficient to control the overall purine biosynthesis and salvage rates of cells. To this end, we directly modulated Prps2 expression levels in freshly isolated primary B cells (Figures 2B, 2C, and S2A) . Upon knockdown of Prps2 expression in primary B cells using small interfering RNA (siRNA) ( Figures 2B and S2A ), we observed a 14% decrease in the rate of [ 14 C] formate incorporation into purines compared to control siRNA-transfected cells ( Figures 2D and 2E) , demonstrating the requirement of PRPS2 enzymatic activity for the optimum rate of de novo purine biosynthesis. Conversely, overexpression of Prps2 in B cells caused a 21% increase in [ 14 C] formate incorporated into purine nucleotides ( Figure 2F ). To assess the contribution of PRPS2 activity toward nucleotide salvage pathway function, we measured [8- 14 C] hypoxanthine labeling of purines upon knockdown or overexpression of Prps2 in B cells (Figure 2G) . Although less dramatic than the effect observed on de novo purine biosynthesis, both knockdown ( Figure 2H ) and overexpression ( Figure 2I ) resulted in significant decreases or increases, respectively, in [
14 C] incorporation. Therefore, PRPS2 levels are rate limiting and important for controlling nucleotide biosynthesis rates, revealing a key enzyme that promotes nucleotide metabolism and is regulated at the posttranscriptional level by Myc hyperactivation.
Prps2, but not Prps1, Gene Expression Is Regulated Acutely at the Translational Level Given the critical importance of PRPS2 protein levels in purine metabolic flux, we hypothesized that translational control of Prps2 gene expression may serve at the interface of protein and nucleotide biosynthesis control. To address whether translational control of Prps2 may provide a rapid and dynamic mechanism to regulate purine synthesis, we acutely and rapidly induced mitogen-dependent protein synthesis in serum-starved cells by 30 min of serum stimulation (Geyer et al., 1982) . Strikingly, the levels of PRPS2 protein, but not mRNA, increased dramatically upon addition of serum, suggesting that Prps2 may be regulated at the translation level ( Figures 3A and 3B ). To test this hypothesis, we employed ribosome sucrose-gradient fractionation. Indeed, upon 30 min of serum stimulation, we observe an increase in the amount of Prps2 mRNA associated with heavy polyribosomes fractions, containing highly translating mRNAs, compared to serum-starved cells ( Figures 3C and 3D ). Moreover, Prps2 showed the same acute translational activation as other growth factor-responsive genes, such as Ribosomal Protein S3 (Rps3), a bona fide translationally regulated mRNA, and c-Myc ( Figures  S3A-S3C ), that respond immediately and rapidly to acute serum stimulation.
Notably, although there are two isoforms of PRPP synthetase expressed in somatic tissues, only Prps2, and not Prps1, displays increased translation upon serum stimulation ( Figure 3C ). Interestingly, the PRPS2 isoform is largely resistant to feedback inhibition by the nucleotide biosynthesis products ADP and GDP that is a feature of the PRPS1 enzyme (Nosal et al., 1993) . This enzymatic property of PRPS2 may facilitate the unrestrained, elevated production of nucleotides observed in Myc-overexpressing cells, as well as explain why the levels of PRPS2, but not PRPS1, are increased in cancer cells. The translational regulation of Prps2 is highly specific, as other members of the purine biosynthetic pathway are not regulated in this manner ( Figure 3A) . Therefore, translational control of Prps2 is a rapid sensor of the total rate of protein biosynthesis within the cell, which precedes biomass accumulation.
Prps2
Translation Is Controlled by the eIF4E Oncogene through a Conserved cis-Acting Regulatory Element that Directs Nucleotide Production An unresolved question is how Prps2, but not other members of the purine biosynthesis pathway, is specifically and acutely regulated at the translation level downstream of Myc hyperactivation. Progrowth signals, such as serum stimulation and Myc hyperactivation, are thought to regulate translation of specific subsets of mRNAs through increases in the activity of the major cap-binding protein, eIF4E Ruggero et al., 2004; Topisirovic and Sonenberg, 2011) . Importantly, eIF4E is also a direct transcriptional target of Myc (Jones et al., 1996) and is a master regulator of the rate-determining step in translation initiation. Upon forced overexpression of Myc, we also observe an increase in eIF4E levels that coincides with elevated Prps2 expression ( Figures S3D and S3E ). Therefore, using specific inhibitors that target the activity of eIF4E, we tested whether the effects of Prps2 translational control are mediated through eIF4E hyperactivation. Specifically, we pretreated serumstarved fibroblasts with either an mTOR active-site inhibitor (MLN0128), which blocks the phosphorylation of eIF4E binding protein 1 (4EBP1), or with a MEK1/2 inhibitor (PD901), which impairs eIF4E phosphorylation. Notably, in both of these treatments, we observe that the increases in PRPS2 protein levels present upon acute serum stimulation are abolished (Figures 3E and 3F) .
To extend our findings demonstrating eIF4E-mediated translational control of Prps2 mRNA in vivo, we employed a genetic (legend continued on next page) system to specifically express a doxycycline-inducible dominant-negative eIF4E binding protein 1 (DN-4EBP1) transgene in B cells ( Figure 4A ) Pourdehnad et al., 2013) . This genetic strategy neither perturbs global protein synthesis nor cell viability but rather only affects the translation of eIF4E rate-limiting target mRNAs . The inducible downregulation of eIF4E activity decreased expression of PRPS2 protein ( Figure 4B ) without affecting Prps2 mRNA levels ( Figure S4A ). Importantly, eIF4E-dependent translational control within the nucleotide biosynthesis pathway is selective for Prps2 as the expression levels of additional key enzymes in this pathway, such as IMPDH2, PPAT, and ATIC, remain unchanged in DN-4EBP1 transgenic mice ( Figure 4B ). c-Myc expression is also unaffected by inhibition of eIF4E in Em-Myc/+-derived B cells (Pourdehnad et al., 2013 We next tested whether a specific sequence or motif could be responsible for the translational regulation of Prps2. A recently identified, important eIF4E cis-regulatory element that confers translational specificity is the pyrimidine-rich translational element (PRTE) (Hsieh et al., 2012) . Consistent with our findings that Prps2, and not Prps1, is regulated at the level of translational control, only Prps2 contains a consensus PRTE motif within its 5 0 UTR ( Figure S4C ). To test the possibility that Prps2 displays differential sensitivity to translational regulation by eIF4E, we constructed luciferase reporter constructs fused to the 5 0 UTR of Prps1 and Prps2, as well as deletion and transversion mutants of the PRTE domain within Prps2. Strikingly, transfection of these reporter constructs revealed that the PRTE motif is sufficient to direct translational control of Prps2 in an eIF4E-dependent manner and that the related PRPS1 isoform is not regulated by this mode of translational control ( Figures 4D and S4D ). Additionally, the WT Prps2 5 0 UTR luciferase reporter was selectively activated in Myc-overexpressing cells, whereas the Prps2 5 0 UTR PRTE deletion reporter and Prps1 5 0 UTR reporter were not (Figure 4E) , therefore confirming the direct link between Myc-overexpression and increased Prps2 gene expression through a unique eIF4E-dependent cis-acting regulatory element. Importantly, other genes of the nucleotide biosynthesis pathway lack this functional motif within their 5 0 UTRs (data not shown; Figure S4C) . Thus, Prps2 possesses a functional translational enhancer element within its 5 0 UTR that may act as a critical bottleneck in the production of nucleotides in cancer that is coupled to protein synthesis. To further define the precise contribution of translational control of Prps2 toward nucleotide biosynthesis, we employed fibroblasts derived from Prps2 null mice (see Figures 6 and S6 for details regarding generation of Prps2 null mice). We transfected mRNAs encoding FLAG-PRPS2 fused to either the WT 5 0 UTR of Prps2 or the 5 0 UTR of Prps2 engineered to lack the pyrimidine-rich translational element (DPRTE), which confers sensitivity to eIF4E-mediated translation control. Importantly, only Prps2 null cells transfected with the Prps2 5 0 UTR, FLAG-PRPS2, but not the DPRTE 5 0 UTR mutant, displayed a serum-dependent increase in translation of FLAG-PRPS2 protein and increased purine nucleotide production ( Figures 4F and 4G) . Therefore, the PRTE sequence in Prps2 mRNA acts as a dynamic sensor that couples protein biosynthesis with nucleotide production.
PRPS2 Knockdown Is Synthetically Lethal in Myc-Overexpressing Cells and Blocks Myc-Dependent Tumor Initiation and Maintenance In Vivo
We tested whether inhibiting translational regulation of Prps2 mRNA could represent a potential synthetic lethal interaction with Myc hyperactivation. We observe a dramatic increase in Prps2 translation upon oncogenic cellular transformation driven by Myc and Ras that relies on eIF4E activity, demonstrating that translational regulation of Prps2 occurs as an early event during oncogenic transformation ( Figure 5A ). This is consistent with the upregulation in PRPS2 protein during the early pretumor stage of Myc-driven lymphomagenesis ( Figure 1F ). Next, to directly address the functional relevance of increased Prps2 expression in cellular transformation, we performed knockdown of Prps2 in Ras and Myc-transformed MEFs. Strikingly, we observed a 70% increase in apoptosis upon Prps2 knockdown in transformed, but not WT, cells ( Figure 5B ). Importantly, this increase in apoptosis was specific to the knockdown of the PRPS2 isozyme, as knockdown of PRPS1 did not affect cellular viability in normal or transformed MEFs (Figures 5B and S5A) .
We next wanted to address why PRPS2 loss, but not PRPS1 loss, is deleterious for the viability of Myc-overexpressing transformed MEFs. Whereas siRNA-mediated knockdown of either PRPS2 or PRPS1 led to only a modest decrease in purine nucleotide production in WT MEFs, knockdown of PRPS2, but not PRPS1, resulted in a dramatic decrease in purine nucleotide production in MEFs transformed by Myc and Ras overexpression ( Figure S5B ). Additionally, knockdown of PRPS1 or PRPS2 in WT MEFs produced similar decreases in the rates of RNA and DNA production ( Figures S5C and S5D) . These results suggest that, whereas PRPS2 and PRPS1 play interchangeable roles in normal cells, Myc-overexpressing cancer cells rely on the specific activity of PRPS2 to produce the nucleotides necessary to For all graphs, error bars represent SD; n = 6; **p < 0.01, *p < 0.05 by Student's t test. See also Figure S2 .
sustain their metabolic demands. Because Myc overexpression is known to sensitize cells to apoptosis, loss of function of PRPS2 may exacerbate the apoptotic program normally regulated by Myc. To test this possibility, we generated cells that overexpress apoptosis-resistant Myc amino acid substitution mutant alleles (Graves et al., 2010; Hemann et al., 2005) . Each mutant tested (P57S, F138C, and T58A) was able to increase the expression of the nucleotide biosynthetic pathway enzymes PPAT, UMPS, and PRPS2 to similar degrees ( Figure 5C ) and, importantly, retained the sensitivity to programmed cell death induced by PRPS2 knockdown ( Figure 5D ). Taken together, these results suggest that loss of function of PRPS2 does not simply augment the apoptotic program already regulated by Myc but rather disrupts the Myc-dependent metabolic program in cancer cells, leading to synthetic lethality. We next tested the potential therapeutic effects of PRPS2 knockdown in vivo. We observe a 40% induction of apoptosis ( Figure 5E ) in Myc-overexpressing B cells, but not in normal cells, upon PRPS2 knockdown in a pretumor setting. Upon induced expression of Prps2 short hairpin RNA (shRNA) in vivo, we also observed an increase in apoptosis of Myc-expressing cells within the tumor setting ( Figures 5F and 5G) . Notably, mice induced to express shRNA directed toward Prps2 showed a significant delay in Myc-driven tumor onset ( Figure 5H ). We next assessed the therapeutic efficacy of PRPS2 loss of function in established Myc-driven lymphomas. After tumor formation, Prps2 shRNA expression was induced and tumor progression was monitored ( Figures 5I and S5F ). We observed a strong impairment in tumor progression upon knockdown of Prps2, and remarkably, at least 30% of these mice displayed complete tumor regression and survival beyond 7 months of age, revealing a critical oncogenic role of PRPS2.
Generation of a Prps2 Knockout Mouse Reveals that PRPS2 Is Dispensable for Normal Physiology and Cellular Function but Is Required for Metabolic Homeostasis in Myc-Overexpressing Cells
A remaining question is whether PRPS2 is normally essential for cell and organismal physiology in vivo. To address this question, we generated a Prps2 knockout mouse ( Figure S6A ). Strikingly, mice homozygous null for the Prps2 gene (Prps2 null ) are viable and fertile and display no gross phenotypic abnormalities, despite lacking Prps2 mRNA and protein expression ( Figures  S6B and S6C) . Notably, there was no compensatory upregulation of Prps1 mRNA levels in tissues from Prps2 null mice, suggesting that normal expression levels and enzymatic activity of PRPS1 are sufficient to maintain metabolic homeostasis ( Figure S6C ). As the critical nucleotide biosynthetic intermediate, PRPP is only produced by PRPS enzymes; these findings are consistent with the continued activity of the PRPS1 isozyme, whose mRNA is interestingly normally found expressed at higher levels than Prps2 in all tissues we surveyed ( Figures S6C and S6D) . We next investigated the function of PRPS2 in normal B cell homeostasis. In Prps2 null mice, Prps1 expression in splenic B cells was maintained at the same levels observed in WT cells ( Figures 6A and 6B ). Complete loss of Prps2 expression did not alter spleen weight, tissue architecture, or morphology (Figures 6C, 6D , and S6E). Moreover, the percent of B lymphocytes present in the spleen ( Figure 6E ), as well as B cell size (Figure S6F) , cell-cycle distribution ( Figure S6G ) or cell viability (Figure S6H) , was not altered. Although Prps2 null B lymphocytes display no overt phenotypic differences, they do have a minor decrease in rates of purine nucleotide biosynthesis, which are further decreased upon siRNA-mediated knockdown of the PRPS1 isozyme ( Figure 6F ). Together, these results suggest that the activity of PRPS1 alone is sufficient to maintain the normal function of B lymphocytes and spleen development, whereas PRPS2 function is dispensable. As PRPS2 shares $95% amino acid identity with the PRPS1 isoform (Becker et al., 1990) , it remains unknown whether cancer cells have evolved a mechanism to promote cell survival through only one of the two PRPS isoforms. To address this question, we utilized Prps2 null MEFs engineered to overexpress a ligand-activatable MycER allele (Eilers et al., 1989) . Notably, treatment with 4-hydroxytamoxifen to activate Myc increased only PRPS2, but not PRPS1, protein abundance ( Figure 6G ). Strikingly, our data demonstrate that the Myc-dependent increase in the purine nucleotide production rate can be completely restored to WT levels in Em-Myc/+;Prps2 null B cells ( Figure 6H ). Therefore, these results suggest a specific requirement for PRPS2, but not PRPS1, function in maintaining the metabolic homeostasis of Myc-overexpressing cells.
We then sought to determine the most immediate effects of nucleotide production driven by PRPS2 downstream of Myc hyperactivation. An increased pool of RNA nucleotides is utilized by cancer cells for incorporation into rRNA and tRNA to generate increased numbers of ribosomes (Ben-Sahra et al., 2013) . In addition, sufficient pools of deoxyribonucleotides are also required to maintain DNA fidelity during replication (Bester et al., 2011) and to bypass oncogene-induced senescence (legend continued on next page) (Aird et al., 2013) . Importantly, in Em-Myc/+;Prps2 null B cells, the decrease in overall nucleotide production leads to overall decreases in the rate of ribo-and deoxyribo-nucleic acid production compared to Myc-overexpressing B cells (Figures 6I and  6J ). As total cellular RNA is predominantly comprised of ribosomal RNA, we next examined whether the augmented rates of protein synthesis evident upon Myc hyperactivation are altered in Em-Myc/+;Prps2 null B cells. Indeed, our data demonstrate that the overall rate of protein synthesis in Em-Myc/+ B lymphocytes, but not in normal B cells, is decreased toward normal levels in Prps2 null mice ( Figure 6K ). Importantly, limiting the protein synthetic capacity in Em-Myc/+ B cells by genetic or pharmacological means has been previously shown to promote increased programmed cell death (Barna et al., 2008; Bywater et al., 2012) . These findings suggest a possible mechanism for the synthetic lethality observed in Myc-overexpressing cells upon loss of PRPS2 function.
Interference with glucose metabolism has also been shown to limit oncogenic potential or promote apoptosis in Myc-overexpressing cells (Doherty et al., 2014; Faubert et al., 2013; Shim et al., 1998) . Normal cells lacking PRPS2 display little to no difference in glucose uptake or in the rate of lactate production, glucose oxidation, and glucose conversion to purines, RNA, and DNA ( Figures S7A-S7F Figure 7C ). To extend our observations to human cancers, we employed two Burkitt's lymphoma cell lines, Daudi and Raji, and two Multiple Myeloma cell lines, U266 and JJN-3, where Myc is found translocated and/or overexpressed. Knockdown of PRPS2 in these Myc-dependent cell lines resulted in a marked increase in apoptosis, revealing that PRPS2 expression is required to sustain cancer cell survival in both mouse and human cancers that rely on Myc hyperactivation ( Figures 7D and S7I ).
DISCUSSION The Role of Translational Control in Cellular Metabolism
Our findings point to a model whereby translational regulation of PRPS2 couples protein synthesis to metabolism and directly acts as a molecular rheostat for the nucleotide biosynthesis pathway in cancer cells, controlling the flow of ribose-5-phosphate from the pentose phosphate pathway into the nucleotide biosynthetic precursor PRPP ( Figure 7E ). Therapeutic strategies that interfere with this Myc-dependent translational control or direct inhibition of PRPS2 expression create a ''bottleneck'' between the pentose phosphate pathway and nucleotide precursors to decrease the elevated nucleotide production that is specifically required for cancer, but not for normal cell survival, and consequently, tumor initiation and progression. The ability to translationally up-or downregulate mRNAs that encode enzymes capable of controlling metabolic flux ensures a quick response to the protein synthesis demands of cancer cells. Myc-overexpressing cells lacking PRPS2 have a reduced capacity to increase protein synthesis, likely as a consequence of the observed decrease in nucleotide production that is required to synthesize ribosomes. Therefore, Myc-overexpressing cells establish a feedforward mechanism that tethers increased protein synthesis rates to nucleotide production in order to sustain their continued growth. In line with our findings, restriction of either protein synthesis capacity or ribosome biogenesis has been directly implicated as synthetically lethal in Myc-overexpressing cells (Barna et al., 2008; Bywater et al., 2012) . The reliance of key oncogenes, such as Myc, on the posttranscriptional regulation of PRPS2 reveals a significant vulnerability to the maintenance of cancer cell homeostasis. In fact, our data demonstrate that growth-factor-dependent increases in Prps2 translation can be blocked by kinase inhibitors of mTOR or MEK1/2, which converge on eIF4E activity. Therefore, the identification of PRPS2 as a key, translationally regulated enzyme may have broad implications for metabolic control in many additional cancer types driven by distinct oncogenic signals, such as mTOR, where the translation of PRTE-containing mRNAs are increased.
PRPS2 shares $95% amino acid identity with the PRPS1 isoform (Becker et al., 1990) . However, our data demonstrate that translational upregulation of PRPS expression by oncogenic signals occurs exclusively on the PRPS2 isozyme. Distinguishing Error bars represent SD; n = 4; ***p < 0.001, **p < 0.01, *p < 0.05 by Student's t test. See also Figure S4 .
biochemical features of the PRPS2 enzyme present intriguing insight as to why it may be favored to promote nucleotide biosynthesis in oncogenic cells. First, PRPS2 has been demonstrated to be more resistant to the allosteric feedback inhibition by nucleotide biosynthetic pathway byproducts ADP and GDP (Nosal et al., 1993) . This enzymatic property may allow PRPS2-expressing cells to continue biosynthesis of nucleotides when their intracellular concentrations are elevated. Additionally, PRPS2 activity is more sensitive to fluctuations in the concentration of its substrate, ATP, which is present at elevated concentrations in Myc-overexpressing B cells ( Figures 1B and S1A ) (Nosal et al., 1993) . These distinguishing enzymatic properties of the different PRPS isoforms suggest a biochemical basis for the development of specific inhibitors to selectively inhibit PRPS2.
PRPS2 as a Therapeutic Target
The Myc oncogene is currently undruggable. Because PRPS2 is an enzyme, it is considered part of the druggable genome (Hopkins and Groom, 2002) . Surprisingly, although loss of expression of Prps2 resulted in a modest decrease in nucleotide production in normal cells, there are no apparent deleterious effects at the organismal level in Prps2 null mice. Furthermore, we show a therapeutic benefit upon loss-of-function of PRPS2 from the earliest stage of premalignancy through the later stages of fully formed tumors, indicating that PRPS2-dependent nucleotide production is an important, defining feature necessary for cancer cell survival. Therefore, drugs capable of specifically inhibiting the PRPS2 isoform may possess a selective therapeutic window.
Inhibitors targeting the nucleotide biosynthetic pathway have long been utilized as chemotherapeutic agents in the clinic. However, many of these drugs produce significant toxicities in widespread organs. Antifolates, which interfere with the one carbon cycle, indiscriminately decrease nucleotide biosynthesis in all proliferating tissues. Other drugs that specifically inhibit the production of one of the five pyrimidine or purine nucleotides disrupt the delicate balance within the nucleotide pools, which leads to incorporation of improper bases into the genetic code and results in DNA damage and/or defective gene expression. Our data demonstrating that PRPS2 is a central integrator of the two most abundant classes of macromolecules comprising cells-proteins and nucleic acids-strongly suggests a distinct therapeutic window exploiting the synthetic lethal interactions important for metabolic reprogramming in cancer cells.
EXPERIMENTAL PROCEDURES
Detailed experimental procedures can be found in the Extended Experimental Procedures. All experimental procedures performed on mice were approved by the UCSF Institutional Animal Care and Use Committees.
Magnetic Resonance Data Acquisition and Processing
One-dimensional 1 H MR spectra acquisition was performed on the aqueous fraction of freshly isolated B cell extracts described in the Extended Experimental Procedures using a 600 MHz Bruker spectrometer equipped with a cryogenically cooled probe. A 90 pulse and 4 s relaxation delay were used, and the water resonance was suppressed using excitation sculpting (Hwang and Shaka, 1995) . All magnetic resonance spectroscopy (MRS) data sets were processed using NMRLab in the MATLAB programming environment (The MathWorks) (Gü nther et al., 2000) . Following standard processing steps, selected signals arising from residual solvents and from trimethylsilyl propanoic acid were excluded, and spectra were normalized according to the probabilistic quotient method (Dieterle et al., 2006) . For all data sets, MRS resonances of metabolites were assigned by comparison with spectra of standard compounds (Ludwig et al., 2011) . Peak integrals of selected metabolites were calculated using ACD/Spec Manager (v. 9.15) software (Advanced Chemistry Development) and normalized to the mean of WT samples for relative quantification. Statistical significance was determined using a Student's t test with p < 0.05 considered significant (n = $8/genotype). Metabolic labeling experiments were performed as described (Boss and Erbe, 1982; White et al., 1975) For all experiments, error bars represent SD and n = 4 for (B), (D), and (E), and n = 3 for (G). **p < 0.01, *p < 0.05, ns, not significant by Student's t test. See also Figure S5 .
Metabolic Flux Experiments
Sucrose Gradient Fractionation and Polysome Profiling
Sucrose gradient fractionation and polysome profiling were performed as described (Hsieh et al., 2012) . Upon polysome fractionation, RNA was extracted and purified using Trizol reagent and PureLink RNA isolation kits (Invitrogen). RNA isolated from each fraction was reverse transcribed, and quantitative real-time PCR analysis of polysomal fractions was performed using primers listed in the Extended Experimental Procedures. Data are normalized to 5S rRNA expression and subsequently expressed as a fraction of total mRNA for either Prps1 or Prps2.
Luciferase Reporter Assays NIH 3T3 cells were transfected with Prps2 or Prps1 5 0 UTR pGL3 promoter plasmids in presence of DN-4EBP1 pMSCV hygro or empty vector control in six-well dishes using lipofectamine (Invitrogen). Twenty-four hours posttransfection, cells were harvested and lysed in passive lysis buffer (Promega), and luciferase assays were performed using a Promega Glomax instrument as described previously (Hsieh et al., 2012) .
Fetal Liver Hematopoietic Stem Cell Culture, Retroviral Preparation, Infection, and Transplantation Fetal liver hematopoietic stem cell (HSC) culture, infection, and transplantation were performed as described with slight variation (Zuber et al., 2011) . Retroviral constructs used to transduce HSCs with GFP-expressing Tet-PRPS2 shRNA is described in the Extended Experimental Procedures. Efficacy of infection was assessed by fluorescence-activated cell sorting (FACS) analysis to determine the percentage of GFP-positive cells. For all transplanted recipient mice, more than 60% of donor HSCs were infected. Tumor-free survival was monitored twice weekly by palpating lymph nodes. Survival data were plotted using GraphPad Prism software. p values were calculated using the log rank test.
Em-Myc/+ Tumor Cell Culture, Infection, Transplantation, and Monitoring Em-Myc tumor cells were harvested, cultured, and infected with Tet-PRPS2 shRNA MSCV-pGFP as described (Schmitt et al., 2000) . A detailed description is presented in the Extended Experimental Procedures. After transplantation via tail vein of 5 3 10 6 live tumor cells into syngeneic recipients, tumors were allowed to engraft for several days. Between days 5 and 7 posttransplantation, blood samples from tail bleeds were subjected to FACS analysis to assay for tumor take by measurement of GFP + B220 + tumor cells. Upon detection of GFP + population of circulating B220 + cells, mice were placed in either vehicle (water) or doxycycline (2 mg/ml in water) treatment regimens representing day 0 of the survival curve. Survival was monitored daily, and mice were sacrificed upon becoming moribund or developing tumors >1 cm in diameter. Survival data were plotted using GraphPad Prism software. p values were calculated using the log rank test. 
Generation of
